Cancer Treatment Reviews
Volume 26, Issue 5 , Pages 363-376 , October 2000

The effect of chemotherapy on the growing skeleton

  • B.L. van Leeuwen

      Affiliations

    • Department of Surgical Oncology, Groningen University Hospital, P.O. Box 30.001, Groningen, RB, 9700, The Netherlands
    • ,
  • W.A. Kamps

      Affiliations

    • Children’s Cancer Centre, Groningen University Hospital, P.O. Box 30.001, Groningen, RB, 9700, The Netherlands
    • ,
  • H.W.B. Jansen

      Affiliations

    • Bioscan, Laboratory for Medical Device Evaluation, Prof. Bronkhorstlaan 10-D, Bilthoven, MB, 3723, The Netherlands
    • ,
  • H.J. Hoekstra

      Affiliations

    • Department of Surgical Oncology, Groningen University Hospital, P.O. Box 30.001, Groningen, RB, 9700, The Netherlands

References 

    REFERENCES
  1. Mangano JJ. A rise in the incidence of childhood cancer in the United States. Int. J Health Serv. 1999;29:393–408
  2. Linet MS, Ries LAG, Smith MA, Tarone RE, Devesa SS. Recent trends in childhood cancer incidence and mortality in the United States. J Nat Cancer Inst. 1999;91:1051–1058
  3. Meadows AT, Black B, Nesbit-ME J. Long-term survival. Clinical care, research, and education. Cancer. 1993;71:3213–3215
  4. Karnofsky DA. Late effects of immunosuppressive anticancer drugs. Fed Proc. 1967;26:925–933
  5. Anderson V, Godber T, Smibert E, Ekert H. Neurobehavioural sequelae following cranial irradiation and chemotherapy in children: an analysis of risk factors. Pediatr Rehabil. 1997;1:63–76
  6. Ried H, Zietz H, Jaffe N. Late effects of cancer treatment in children. Pediatr Dent. 1995;17:273–284
  7. Pinkerton CR. Avoiding chemotherapy related late effects in children with curable tumours. Arch Dis Child. 1992;67:1116–1119
  8. Bleyer WA. Cancer chemotherapy in infants and children. Pediatr Clin North Am. 1985;32:557–574
  9. Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg HM, Tabin CJ. Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein [see comments]. Science. 1996;273:613–622
  10. Pathi S, Rutenberg JB, Johnson RL, Vortkamp A. Interaction of Ihh and BMP/Noggin signaling during cartilage differentiation. Dev Biol. 1999;209:239–253
  11. Ferguson CM, Miclau T, Hu D, Alpern E, Helms JA. Common molecular pathways in skeletal morphogenesis and repair. Ann N Y Acad Sci. 1998;857:33–42
  12. Lanske B, Karaplis AC, Lee K. PTH/PTHrP receptor in early development and Indian hedgehog regulated bone growth [see comments]. Science. 1996;273:663–666
  13. St-Jaques B, Hammerschmidt M, McMahon AP. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 1999;13:2072–2086
  14. Kronenberg HM, Lanske B, Kovacs CS. Functional analysis of the PTH/PTHrP network of ligands and receptors. Recent Prog Horm Res. 1998;53:283–303
  15. Kameda T, Koike C, Saitoh K, Kuroiwa A, Iba H. Developmental patterning in chondrocytic cultures by morphogenic gradients: BMP induces expression of Indian hedgehog and Noggin. Genes Cells. 1999;4:175–184
  16. Chung U, Lanske B, Lee KE, Li E, Kronenberg H. The parathyroid hormone/parathyroid hormone-related pepetide receptor coordinates endochondral bone development by directly controlling chondrocyte differentiation. Proc Natl Acad Sci USA. 1998;95:13030–13035
  17. Gibson G. Active role of chondrocyte apoptosis in endochondral ossification. Microsc Res Tech. 1998;43:191–204
  18. Mansfield K, Rajpurohit R, Shapiro IM. Extracellular phosphate ions cause apoptosis of terminally differentiated epiphyseal chondrocytes. J Cell Physiol. 1999;179:276–286
  19. Harper J, Klagsbrun M. Cartilage to bone—angiogenesis leads the way. Nat Med. 1999;5:617–618
  20. Zerega B, Cermelli S, Bianco P, Cancedda R, Descalzi-Cancedda F. Parathyroid hormone [PTH91–34] and parathyroid hormone-related protein [PTHrP(1–34)] promote reversion of hypertrophic chondrocytes to a prehypertrophic proliferating phenotype and prevent terminal differentia-tion of osteoblast-like cells. J Bone Miner Res. 1999;14:1281–1289
  21. Rajpurohit R, Mansfield K, Ohyama K, Ewert D, Shapiro IM. Chondrocyte death is linked to development of a mitochondrial membrane permeability transition in the growth plate. J Cell Physiol. 1999;179:287–296
  22. Robertson WWJ. Newest knowledge of the growth plate. Clin Orthop. 1990;253:270–278
  23. Gerber H, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 1999;5:623–628
  24. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev. 1996;17:333–368
  25. De Luca F, Uyeda JA, Mericq V. Retinoic acid is a potent regulator of growth plate chondrogenesis. Endocrinology. 2000;141:346–353
  26. Ohlsson C, Isgaard J, Tornell J, Nilsson A, Isaksson O, Lindahl A. Endocrine regulation of longitudinal bone growth. Acta Paediatr. 1993;(Suppl 1.) 391:33–40
  27. Krishna, A. Y. Phillips, L. S. The growth hormone insulin-like growth factor-I axis. Ziegler, T. R.Pierce, G. F.Herndon, D. N. International Symposium on Growth Factors and Wound Healing: Basic Science and Potential Clinical Applications, New York, Springer-Verlag, 1997, 56, 76
  28. Isaksson OG, Lindahl A, Nilsson A, Isgaard J. Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev. 1987;8:426–438
  29. Nilsson A, Lindahl A, Eden S, Isaksson OG. Demonstration of growth hormone receptors in cultured rat epiphyseal chondrocytes by specific binding of growth hormone and immunohistochemistry. J Endocrinol. 1989;122:69–77
  30. Schlechter NL, Russell SM, Spencer EM, Nicoll CS. Evidence suggesting that the direct growth-promoting effect of growth hormone on cartilage in vivo is mediated by local production of somatomedin. Proc Natl Acad Sci USA. 1986;83:7932–7934
  31. Lindahl A, Isgaard J, Nilsson A, Isaksson OG. Growth hormone potentiates colony formation of epiphyseal chondrocytes in suspension culture. Endocrinology. 1986;118:1843–1848
  32. Nilsson A, Carlsson B, Isgaard J, Isaksson OG, Rymo L. Regulation by GH of insulin-like growth factor-I mRNA expression in rat epiphyseal growth plate as studied within-situ hybridization. J Endocrinol. 1990;125:67–74
  33. Wallach S, Carstens-JH J, Avioli LV, Feinblatt JD. Physical and biochemical factors in bone metabolism [editorial]. Calcif Tissue Int. 1992;50:1–4
  34. Hill DJ, Hogg J. Growth factors and the regulation of pre- and postnatal growth. Baillieres Clin Endocrinol Metab. 1989;3:579–625
  35. Ohlsson C, Nilsson A, Isaksson OG, Lindahl A. Effect of growth hormone and insulin-like growth factor-I on DNA synthesis and matrix production in rat epiphyseal chondrocytes in monolayer culture. J Endocrinol. 1992;133:291–300
  36. Kappy MS. Regulation of growth in children with chronic illness. Therapeutic implications for the year 2000. Am J Dis Child. 1987;141:489–493
  37. Hyams JS, Carey DE. Corticosteroids and growth. J Pediatr. 1988;113:249–254
  38. Underwood LE. Growth retardation in chronic disease: possible mechanisms. Acta Paediatr. 1999;428:93–96
  39. Shalet SM, Brennan BM. Growth and growth hormone status following treatment for childhood leukaemia. Horm Res. 1998;50:1–10
  40. Donaldson SS, Wesley MN, DeWys WD, Suskind RM, Jaffe N, van Eys J. A study of the nutritional status of pediatric cancer patients. Am J Dis Child. 1981;135:1107–1112
  41. Glasser DB, Duane K, Lane JM, Healey JH, Caparros-Sison B. The effect of chemotherapy on growth in the skeletally immature individual. Clin Orthop. 1991;262:93–100
  42. Andrassy RJ, Chwals WJ. Nutritional support of the pediatric oncology patient. Nutrition. 1998;14:124–129
  43. Hall K, Brismar K, Thoren M. Update on somatomedin. Acta Paediatr Scand. 1988;347:87–92
  44. Brighton CT. Longitudinal bone growth: the growth plate and its dysfunction. Instructional Course Lectures, American Academy Orthopaedic Surgeons. 1987;3–27
  45. Hermanussen M, Geiger BK, Sippell WG. ‘Negative growth’ in anorexia nervosa assessed by knemometry. Eur J Pediatr. 1987;146:561–564
  46. Acheson RM, Macintyre MN. The effects of acute infection and starvation on skeletal development. A study of young rats. Br J Exp Path. 1958;39:37–45
  47. Alvear J, Artaza C, Vial M, Guerrero S, Muzzo S. Physical growth and bone age of survivors of protein energy malnutrition. Arch Dis Child. 1986;61:257–262
  48. Prader A, Tanner JM, Harnack GAv. Catch-up growth following illness or starvation. J Pediatr. 1963;62:646–659
  49. Davies HA, Didcock E, Didi M, Ogilvy SA, Wales JK, Shalet SM. Growth, puberty and obesity after treatment for leukaemia. Acta Paediatr. 1995;411:45–50
  50. Lippens RJ, Otten BJ, van’t HofMA. Growth of children with acute lymphocytic leukemia: preliminary results. Hamatol Bluttransfus. 1987;30:427–431
  51. Robinson LL, Nesbit-ME J, Sather HN, Meadows AT, Ortega JA, Hammond GD. Height of children successfully treated for acute lymphoblastic leukemia: a report from the Late Effects Study Committee of Childrens Cancer Study Group. Med Pediatr Oncol. 1985;13:14–21
  52. Herber SM, Kay R, May R, Milner RD. Growth of long term survivors of childhood malignancy. Acta Paediatr Scand. 1985;74:438–441
  53. Griffin NK, Wadsworth J. Effect of treatment of malignant disease on growth in children. Arch Dis Child. 1980;55:600–603
  54. Schiliro G, Russo A, Sciotto A, Distefano G, Vigo R. Radiotherapy, chemotherapy, and growth-hormone deficiency [letter]. Lancet. 1976;2:1031–1032
  55. D’Angio GJ. Complications of treatment encountered in lymphoma-leukemia long-term survivors. Cancer. 1978;42:1015–1025
  56. D’Angio GJ, Clatworthy HW, Evans AE, Newton WA, Tefft M. Is the risk of morbidity and rare mortality worth the cure?. Cancer. 1978;41:377–380
  57. Sklar C, Constine LS. Chronic neuroendocrinological sequelae of radiation therapy. Int J Radiation Oncol Biol Phys. 1995;31:1113–1121
  58. Rappaport R, Brauner R. Growth and endocrine disorders secondary to cranial irradiation. Pediatr Res. 1989;25:561–567
  59. Meister LA, Meadows AT. Late effects of childhood cancer therapy. Curr Probl Pediatr. 1993;23:102–131
  60. Clarson CL, Del-Maestro RF. Growth failure after treatment of pediatric brain tumors. Pediatrics. 1999;103:e37
  61. Kirk JA, Raghupathy P, Stevens MM. Growth failure and growth-hormone deficiency after treatment for acute lymphoblastic leukaemia. Lancet. 1987;1:190–193
  62. Pawlaczyk B, Krause W. Growth hormone secretion in children after therapy for acute lymphoblastic leukaemia. Padiatr Grenzgeb. 1990;29:95–97
  63. Berry DH, Elders MJ, Crist W. Growth in children with acute lymphocytic leukemia: a Pediatric Oncology Group study. Med Pediatr Oncol. 1983;11:39–45
  64. Drinnan CR, Miller JD, Guyda HJ, Esseltine DW, Chevalier LM, Freeman CR. Growth and development of long-term survivors of childhood acute lymphoblastic leukemia treated with and without prophylactic radiation of the central nervous system. Clin Invest Med. 1985;8:307–314
  65. Blatt J, Bercu BB, Gillin JC, Mendelson WB, Poplack DG. Reduced pulsatile growth hormone secretion in children after therapy for acute lymphoblastic leukemia. J Pediatr. 1984;104:182–186
  66. Burstein S. Growth disorders after cranial radiation in childhood. J Clin Endocr Metab. 1994;78:1280–1281
  67. Groot LJ, van-Setten P, Otten BJ, van’t Hof MA, Lippens RJ, Stoelinga GB. Shortened and diminished pubertal growth in boys and girls treated for acute lymphoblastic leukaemia. Acta Paediatr. 1996;85:1091–1095
  68. Moell C, Garwicz S, Westgren U, Wiebe T. Disturbed pubertal growth in girls treated for acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1987;4:1–5
  69. Moell C, Garwicz S, Westgren U, Wiebe T, Albertsson WK. Suppressed spontaneous secretion of growth hormone in girls after treatment for acute lymphoblastic leukaemia. Arch Dis Child. 1989;64:252–258
  70. Uruena M, Stanhope R, Chessells JM, Leiper AD. Impaired pubertal growth in acute lymphoblastic leukaemia. Arch Dis Child. 1991;66:1403–1407
  71. Cicognani A, Cacciari E, Rosito P. Longitudinal growth and final height in long-term survivors of childhood leukaemia. Eur J Pediatr. 1994;153:726–730
  72. Waber DP, Urion DK, Tarbell NJ, Niemeyer C, Gelber R, Sallan SE. Late effects of central nervous system treatment of acute lymphoblastic leukemia in childhood are sex-dependent. Dev Med Child Neurol. 1990;32:238–248
  73. Schriock EA, Schell MJ, Carter M, Hustu O, Ochs JJ. Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia. J Clin Oncol. 1991;9:400–405
  74. Talvensaari KK, Knip M, Lanning P, Lanning M. Clinical characteristics and factors affecting growth in long- term survivors of cancer. Med Pediatr Oncol. 1996;26:166–172
  75. Stubberfield TG, Byrne GC, Jones TW. Growth and growth hormone secretion after treatment for acute lymphoblastic leukemia in childhood. 18-Gy versus 24-Gy cranial irradiation. J Pediatr Hematol Oncol. 1995;17:167–171
  76. Makipernaa A, Dunkel L, Siimes MA. Growth after treatment of solid tumours in childhood. Acta Paediatr Scand. 1990;79:817–822
  77. Mithal NP, Almond MK, Evans K, Hoskin PJ. Reduced bone mineral density in long-term survivors of medulloblastoma [published erratum appears in Br J Radiol 1994;67: 219]. Br J Radiol. 1993;66:814–816
  78. Henderson RC, Madsen CD, Davis C, Gold SH. Longitudinal evaluation of bone mineral density in children receiving chemotherapy [see comments]. J Pediatr Hematol Oncol. 1998;20:322–326
  79. Nysom K, Holm K, Michaelsen KF. Bone mass after allogeneic BMT for childhood leukaemia or lymphoma. Bone Marrow Transplant. 2000;25:191–196
  80. Hesseling PB, Hough SF, Nel ED, van Riet FA, Beneke T, Wessels G. Bone mineral density in long-term survivors of childhood cancer. Int J Cancer. 1998;11:44–47
  81. Henderson RC, Madsen CD, Davis C, Gold SH. Bone density in survivors of childhood malignancies. J Pediatr Hematol Oncol. 1996;18:367–371
  82. Hoorweg-Nijman JJ, Kardos G, Roos JC. Bone mineral density and markers of bone turnover in young adult survivors of childhood lymphoblastic leukaemia. Clin Endocrinol (Oxf). 1999;50:237–244
  83. Murray RD, Brennan BM, Rahim A, Shalet SM. Survivors of childhood cancer: long-term endocrine and metabolic problems dwarf the growth disturbance. Acta Paediatr. 1999;88 (Suppl.):5–12
  84. Ochs J, Mulhern R. Long-term sequelae of therapy for childhood acute lymphoblastic leukaemia. Baillieres Clin Haematol. 1994;7:365–376
  85. Nyaruba MM, Yamamoto I, Kimura H, Morita R. Bone fragility induced by X-ray irradiation in relation to cortical bone-mineral content. Acta Radiol. 1998;39:43–46
  86. Hinkel CL. The effect of irradiation upon the composition and vascularity of growing rat bones. Am J Roentg. 1943;50:516–526
  87. Barr JS, Lingley JR, Gall EA. The effect of roentgen irradiation on epiphyseal growth. Am J Roentg. 1943;49:104–115
  88. Markbreiter LA, Pelker RR, Friedlaender GE, Peschel R, Panjabi MM. The effect of radiation on the fracture repair process. A biomechanical evaluation of a closed fracture in a rat model. J Orthop Res. 1989;7:178–183
  89. De-Smet AA, Kuhns LR, Fayos JV, Holt JF. Effects of radiation therapy on growing long bones. Am J Roentgenol. 1976;127:935–939
  90. Hale GA, Marina NM, Jones WD. Late effects of treatment for germ cell tumors during childhood and adolescence. J Pediatr Hematol Oncol. 1999;21:115–122
  91. Meadows AT, Gallagher JA, Bunin GR. Late effects of early childhood cancer therapy. Br J Cancer. 1992;18:S92–S95
  92. Eifel PJ, Sampson CM, Tucker SL. Radiation fractionation sensitivity of epiphyseal cartilage in a weanling rat model. Int J Radiat Oncol Biol Phys. 1990;19:661–664
  93. Eifel PJ. Decreased bone growth arrest in weanling rats with multiple radiation fractions per day. Int J Radiat Oncol Biol Phys. 1988;15:141–145
  94. Rubin P, Andrews JR, Swarm R, Gump H. Radiation induced dysplasias of bone. Am J Roentgen. 1959;82:206–216
  95. Engstrom H, Jansson JO, Engstrom C. Effect of local irradiation on longitudinal bone growth in the rat. A tetracycline labelling investigation. Acta Radiol Oncol. 1983;22:129–133
  96. Bushhouse S, Ramsay NK, Pescovitz OH, Kim T, Robison LL. Growth in children following irradiation for bone marrow transplantation. Am J Pediatr Hematol Oncol. 1989;11:134–140
  97. Vogl T. Wachstumsstörungen durch Schädigung der Epiphysenfuge im Kindesalter infolge therapeutische Radiatio. In:  Pförringer W,  Rosemeyer E editor. Die Epiphysenfugen. München: Perimed Fachbuch-Verslaggesellschaft mbH; 1987;p. 407–411
  98. Pastore G, Zurlo MG, Acquaviva A. Health status of young childen with cancer following discontinuation of therapy. Med Pediatr Oncol. 1987;15:1–6
  99. Kalapurakal JA, Thomas PR. Pediatric radiotherapy. An overview. Radiol Clin North Am. 1997;35:1265–1280
  100. Preece MA. The effect of administered corticosteroids on the growth of children. Postgrad Med J. 1976;52:625–630
  101. Loeb JN. Corticosteroids and Growth. N Engl J Med. 1976;295:547–552
  102. Morris HG. Growth and skeletal maturation in asthmatic children: effect of corticosteriod treatment. Pediatr Res. 1975;9:579–583
  103. Pearce G, Tabensky DA, Delmas PD, Baker HWG, Seeman E. Corticosteroid-induced bone loss in men. J Clin Endocr Metab. 1998;83:801–806
  104. Thakore JH, Dinan TG. Growth-hormone secretion: the role of glucocorticoids. Life Sci. 1994;55:1083–1099
  105. Baxter JD. Mechanisms of glucocorticoid inhibition of growth. Kidney Int. 1978;14:330–333
  106. Dearden LC, Mosier HD, Brundage M, Thai C, Jansons R. The effects of different steroids on costal and epiphyseal cartilage of fetal and adult rats. Cell Tissue Res. 1986;246:401–412
  107. Robson H, Anderson E, Eden OB, Isaksson O, Shalet S. Chemotherapeutic agents used in the treatment of childhood malignancies have direct effects on growth plate chondrocyte proliferation. J Endocrinol. 1998;157:225–235
  108. Efthimiou J, Barnes PJ. Effect of inhaled corticosteroids on bones and growth. Eur Respir J. 1998;11:1167–1177
  109. Reid IR. Glucocorticoid osteoporosis—mechanisms and management. Eur J Endocrinol. 1997;137:209–217
  110. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Cancer. 1995;75:2186–2195
  111. Link, P. M. Pediatric oncology. Pediatr Clin North Am, 1997, 44, 791, 1058
  112. Balis FM, Holcenberg JS, Poplack DG. General principles of chemotherapy. In:  Pizzo PA,  Poplack DG editor. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott-Raven; 1997;p. 215–272
  113. Seitz M. Molecular and cellular effects of methotrexate. Curr Opin Rheumatol. 1999;11:226–232
  114. Serafino A, Sinibaldi-Vallebona P, Pierimarchi P. Induction of apoptotsis in neoplastic cells by anthracycline antitumor drugs: nuclear and cytoplasmic triggering?. Anticancer Res. 1999;19:1909–1918
  115. Silverman FC. Treatment of leukemia and allied disorders with folic acid antagonists; effect of aminopterin on skeletal lesions. Radiology. 1950;54:665–678
  116. Follis HF, Park EA. Some observations on bone growth, with particular respect to zones and transverse lines of increased density in the metaphysis. Am J Roentg Rad Ther Nucl Med. 1952;68:709–724
  117. Ogden JA. Growth slowdown and arrest lines. J Pediatr Orthop. 1984;4:409–415
  118. Waisman HA, Harvey RA. Radiological evidence of growth in children with acute leukemia treated with folic acid antagonists. Radiology. 1954;60:61–64
  119. Sunderman CR, Pearson HA. Growth effects of long-term antileukemic therapy. J Pediatr. 1969;75:1058–1062
  120. Jaffe N. Non-oncogenic sequelae of cancer chemotherapy. Radiology. 1975;114:167–173
  121. Shalet SM. Disorders of the endocrine system due to radiation and cytotoxic chemotherapy. Clin Endocrinol Oxf. 1983;19:637–659
  122. Moell C, Garwicz S, Marky I, Mellander L, Karlberg J. Growth in children treated for acute lymphoblastic leukemia with and without prophylactic cranial irradiation. Acta Paediatr Scand. 1988;77:688–692
  123. Shalet SM. Endocrine sequelae of cancer therapy. Eur J Endocrinol. 1996;135:135–143
  124. Tamminga, R. Y. J. Growth of children with cancer. State University Groningen.
  125. Bar OE, Beckwith JB, Odom LF, Eilert RE. Effect of chemotherapy on human growth plate. J Pediatr Orthop. 1993;13:220–224
  126. Pao WJ, Hustu HO, Douglass EC, Beckford NS, Kun LE. Pediatric nasopharyngeal carcinoma: long term follow-up of 29 patients. Int J Radiat Oncol Biol Phys. 1989;17:299–305
  127. Ogilvy SA, Shalet SM. Effect of chemotherapy on growth. Acta Paediatr. 1995;411:52–56
  128. Halton JM, Atkinson SA, Barr RD. Growth and body composition in response to chemotherapy in children with acute lymphoblastic leukemia. Int J Cancer. 1998;11:81–84
  129. Caruso NM, Mancuso M, Spadaro G, Dibenedetto SP, DiCataldo A, Schiliro G. Growth and growth hormone in children during and after therapy for acute lymphoblastic leukaemia. Eur J Pediatr. 1993;152:730–733
  130. Shalet SM, Price DA. Effect of treatment of malignant disease on growth in children [letter]. Arch Dis Child. 1981;56:235–236
  131. Clayton PE, Morris JP, Price DA. Growth in children treated for acute lymphoblastic leukaemia. Lancet. 1988;2:460–462
  132. Samuelsson BO, Albertsson WK, Rosberg S. Growth and growth hormone secretion after treatment for childhood non-Hodgkin’s lymphoma. Med Pediatr Oncol. 1997;28:27–34
  133. Groot LJ, Otten BJ, van Hof MA, Lippens RJ, Stoelinga GB. Chemotherapy plays a major role in the inhibition of catch-up growth during maintenance therapy for childhood acute lymphoblastic leukemia. Pediatrics. 1995;96:693–695
  134. Rainsford KD. Doxorubicin is a potent inhibitor of interleukin 1 induced cartilage proteoglycan resorption in-vitro. J Pharm Pharmacol. 1989;41:60–63
  135. Robson H, Anderson E, Eden O, Isaksson O, Shalet S. Glucocorticoid pretreatment reduces the cytotoxic effects of a variety of DNA-damaging agents on rat tibial growth-plate chondrocytes in vitro. Cancer Chemother Pharmacol. 1998;42:171–176
  136. Probert JC, Parker BR. The effects of radiation therapy on bone growth. Radiology. 1975;114:155–162
  137. Davies HA, Didcock E, Didi M, Ogilvy SA, Wales JK, Shalet SM. Disproportionate short stature after cranial irradiation and combination chemotherapy for leukaemia. Arch Dis Child. 1994;70:472–475
  138. Doskocil M, Valouch P, Pazderka V. On vertebral body growth. Funct Dev Morphol. 1993;3:149–155
  139. Neuhauser EBD. Growth, differentiation, and disease. Am J Roentg Rad Ther Nucl Med. 1953;69:723–736
  140. Wheeler DL, Vander GR, Wronski TJ, Miller GJ, Keith EE, Graves JE. The short- and long-term effects of methotrexate on the rat skeleton. Bone. 1995;16:215–221
  141. Arikoski P, Komulainen J, Riikonen P, Voutilainen R, Knip M, Kroger H. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study. J Clin Endocr Metab. 1999;84:3174–3181
  142. Arikoski P, Kröger H, Riikonen P, Parviainen M, Voutilainen R, Komulainen J. Disturbance in bone turnover in children with a malignancy at completion of chemotherapy. Med Pediatr Oncol. 1999;33:455–461
  143. Arikoski P, Komulainen J, Riikonen P, Jurvelin JS, Voutilainen R, Kröger H. Reduced bone density at completion of chemotherapy for a malignancy. Arch Dis Child. 1999;80:143–148
  144. Crofton PM, Ahmed SF, Wade JC. Effects of a third intensification block of chemotherapy on bone and collagen turnover, insulin-like growth factor I, its binding proteins and short-term growth in children with acute lymphoblastic leukaemia. Eur J Cancer. 1999;35:960–967
  145. Nysom K, Holm K, Fleischer-Michaelsen K, Hertz H, Müller J, Mølgaard C. Bone mass After treatment for acute lymphoblastic leukemia in childhood. J Clin Oncol. 1998;16:3752–3760
  146. Arikoski P, Komulainen J, Riikonen P. Impaired development of bone mineral density during chemotherapy: a prospective analysis of 46 children newly diagnosed with cancer [see comments]. J Bone Minen Res. 1999;14:2002–2009
  147. Arikoski P, Komulainen J, Voutilainen R. Reduced bone mineral density in long-term survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1998;20:234–240
  148. May KP, West SG, McDermott MT, Huffer WE. The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum. 1994;37:201–206
  149. Crofton PM, Ahmed SF, Wade JC. Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia. J Clin Endocr Metab. 1998;83:3121–3129
  150. May KP, Mercill D, McDermott MT, West SG. The effect of methotrexate on mouse bone cells in culture. Arthritis Rheum. 1996;39:489–494
  151. Friedlaender GE, Tross RB, Doganis AC, Kirkwood JM, Baron R. Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J Bone Joint Surg Am. 1984;66:602–607
  152. Nilsson OS, Bauer HC, Brostrom LA. Comparison of the effects of adriamycin and methotrexate on orthotopic and induced heterotopic bone in rats. J Orthop Res. 1990;8:199–204
  153. Nilsson OS, Bauer HC, Brostrom LA. Methotrexate effects on heterotopic bone in rats. Acta Orthop Scand. 1987;58:47–53
  154. Nilsson OS, Bauer FC, Brostrom LA, Nilsonne U. Effect of the antineoplastic agent methotrexate on experimental heterotopic new bone formation in rats. Cancer Res. 1984;44:1653–1656
  155. Boot AM, Heuvel-Eibrink MM, Hahlen K, Krenning EP, Muinck Keizer-Schrama SM. Bone mineral density in children with acute lymphoblastic leukaemia. Eur J Cancer. 1999;35:1693–1697
  156. Neglia JP, Nesbit MEJ. Care and treatment of long-term survivors of childhood cancer. Cancer. 1993;71:3386–3391
  157. Abramson EC, Gajardo H, Kukreja SC. Hypocalcemia in cancer. Bone Miner. 1990;10:161–169
  158. Abramson EC, Chang J, Mayer M. Effects of cisplatin on parathyroid hormone- and human lung tumor-induced bone resorption. J Bone Miner Res. 1988;3:541–546
  159. Atkinson SA, Fraher L, Gundberg CM, Andrew M, Pai M, Barr RD. Mineral homeostasis and bone mass in children treated for acute lymphoblastic leukemia. J Pediatr. 1989;114:793–800
  160. Byrd R. Late effects of treatment of cancer in children. Pediatr Clin North Am. 1985;32:835–857
  161. Nesbit M, Krivit W, Heyn R, Sharp H. Acute and chronic effects of methotrexate on hepatic, pulmonary, and skeletal systems. Cancer. 1976;37:1048–1057
  162. Von-Hoff DD, Schilsky R, Reichert CM. Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep. 1979;63:1527–1531
  163. Wallach S. Effects of magnesium on skeletal metabolism. Magnes Trace Elem. 1990;9:1–14
  164. Halton JM, Atkinson SA, Fraher L. Mineral homeostasis and bone mass at diagnosis in children with acute lymphoblastic leukemia. J Pediatr. 1995;126:557–564
  165. Halton JM, Atkinson SA, Fraher L. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res. 1996;11:1774–1783
  166. Atkinson SA, Halton JM, Bradley C, Wu B, Barr RD. Bone and mineral abnormalities in childhood acute lymphoblastic leukemia: influence of disease, drugs and nutrition. Int Cancer. 1998;11:35–39
  167. Womer RB. Ifosfamide and paediatrics: should this marriage be saved? [editorial; comment]. Eur J Cancer. 1996;32A:1100–1101
  168. Ashraf MS, Brady J, Breatnach F, Deasy PF, O’Meara A. Ifosfamide nephrotoxicity in paediatric cancer patients. Eur J Pediatr. 1994;153:90–94
  169. de Schepper J, Hachimi-Idrissi S, Verboven M, Piepsz A, Otten J. Renal function abnormalities after ifosfamide treatment in children. Acta Paediatr. 1993;82:373–376
  170. Loebstein R, Atanackovic G, Bishai R. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol. 1999;39:454–461
  171. Rossi R, Pleyer J, Schafers P. Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Med Pediatr Oncol. 1999;32:177–182
  172. Relf M, Boal DK. Rickets—a complication of ifosfamide chemotherapy for Wilms tumor. Pediatr Radiol. 1992;22:209–210
  173. Skinner R, Sharkey IM, Pearson AD, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol. 1993;11:173–190
  174. Pratt CB, Meyer WH, Jenkins JJ. Ifosfamide, Fanconi’s syndrome, and rickets. J Clin Oncol. 1991;9:1495–1499
  175. Skinner R, Pearson AD, Price L, Cunningham K, Craft AW. Hypophosphataemic rickets after ifosfamide treatment in children. BMJ. 1989;298:1560–1561
  176. Segal LS, Palumbo RC, Robertson WW. The development of rickets as a complication of chemotherapy for the treatment of Wilms’ tumor. Orthopedics. 1995;18:261–264
  177. Rossi R, Helmchen U, Schellong G. Tubular function and histological findings in ifosfamide-induced renal Fanconi syndrome—a report of two cases. Eur J Pediatr. 1992;151:384–387
  178. Burk CD, Restaino I, Kaplan BS, Meadows AT. Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor [see comments]. J Pediatr. 1990;117:331–335
  179. Newbury-Ecob RA, Noble VW, Barbor PR. Ifosfamide-induced Fanconi syndrome [letter] [see comments]. Lancet. 1989;1:1328
  180. Warner JT, Evans WD, Webb DK, Bell W, Gregory JW. Relative osteopenia after treatment for acute lymphoblastic leukemia. Pediatr Res. 1999;45:544–551
  181. Aisenberg J, Hsieh K, Kalaitzoglou G. Bone mineral density in young adult survivors of childhood cancer. J Pediatr Hematol Oncol. 1998;20:241–245
  182. Brennan BMD, Rahim A, Adams JA, Eden OB, Shalet SM. Reduced bone mineral density in young adults following cure of acute lymphoblastic leukaemia in childhood. Br J Cancer. 1999;79:1859–1863
  183. Kaste SC, Chesney RW, Hudson MM, Lustig RH, Rose SR, Carbone LD. Bone mineral status during and after therapy of childhood cancer: an increasing population with multiple risk factors for impaired bone health [editorial; comment]. J Bone Miner Res. 1999;14:2010–2014
  184. Warner JT, Bell W, Webb DK, Gregory JW. Daily energy expenditure and physical activity in survivors of childhood malignancy. Pediatr Res. 1998;43:607–613
  185. Slemenda CW, Miller JZ, Hui SL, Reister TK, Johnston CC. Role of physical activity in the development of skeletal mass in children. J Bone Minen Res. 1991;6:1227–1233
  186. Rosenstock JG, Jones PM, Pearson D, Palmer MK. Ewing’s sarcoma, adjuvant chemotherapy and pathologic fracture. Eur J Cancer. 1978;14:799–803
  187. Hoekstra HJ, Veth RP, Veldhuis EF, Postma A. A pertrochanteric fracture in an adolescent treated for an osteogenic sarcoma of the shaft of the femur with chemotherapy, tumour resection and endoprosthesis. Arch Orthop Trauma Surg. 1984;103:224–226
  188. Ragab AH, Frech RS, Vietti TJ. Osteoporotic fractures secondary to methotrexate therpay of acute leukemia in remission. Cancer. 1970;25:580–585
  189. Stanisavljevic S, Babcock AL. Fractures in children treated with methotrexate for leukemia. Clin Orthop. 1977;125:139–144
  190. Van-Vleet JF, Ferrans VJ. Clinical and pathologic features of chronic adriamycin toxicosis in rabbits. Am J Vet Res. 1980;41:1462–1469
  191. Tefft M, Lattin PB, Jereb B. Acute and late effects on normal tissues following combined chemo- and radiotherapy for childhood rhabdomyosarcoma and Ewing’s sarcoma. Cancer. 1976;37:1201–1217
  192. Ryan BR, Walters TR. Slipped capital femoral epiphysis following radiotherapy and chemotherapy. Med Pediatr Oncol. 1979;6:279–283
  193. Barrett IR. Slipped capital femoral epiphysis following radiotherapy. J Pediatr Orthop. 1985;5:268–273
  194. Dickerman JD, Newberg AH, Moreland MD. Slipped capital femoral epiphysis (SCFE) following pelvic irradiation for rhabdomyosarcoma. Cancer. 1979;44:480–482
  195. Rubin P. The Franz Buschke lecture: late effects of chemotherapy and radiation therapy: a new hypothesis. Int J Radiat Oncol Biol Phys. 1984;10:5–34
  196. Veth RP, De-Graaf SSN, Den-Heeten GJ. Epiphyseal fractures in children treated for osteosarcoma of the femur with chemotherapy, tumourresection and endoprosthesis: report of four fractures in two children. J Surg Oncol. 1984;26:40–46
  197. Chapman JA, Deakin DP, Green JH. Slipped upper femoral epiphysis after radiotherapy. J Bone Joint Surg Br. 1980;62:337–339
  198. Walker SJ, Whiteside LA, McAlister WH, Silverman CL, Thomas PR. Slipped capital femoral epiphysis following radiation and chemotherapy. Clin Orthop. 1981;159:186–193
  199. Prindull G, Weigel W, Jentsch E, Enderle A, Willert HG. Aseptic osteonecrosis in children treated for acute lymphoblastic leukemia and aplastic anemia. Eur J Pediatr. 1982;139:48–51
  200. Ihde DC, DeVita VT. Osteonecrosis of the femoral head in patients with lymphoma treated with intermittent combination chemotherapy (including corticosteroids). Cancer. 1975;36:1585–1588
  201. Obrist R, Hartmann D, Obrecht JP. Osteonecrosis after chemotherapy [letter]. Lancet. 1978;1:1316
  202. Harper PG, Trask C, Souhami RL. Avascular necrosis of bone caused by combination chemotherapy without corticosteroids. Br Med J Clin Res Ed. 1984;288:267–268
  203. Sty JR, Babbitt DP, Boedecker RA. Bone scintigraphy: methotrexate associated bone necrosis. Wis Med J. 1979;78:32–33
  204. Marymont JV, Kaufman EE. Osteonecrosis of bone associated with combination chemotherapy without corticosteroids. Clin Orthop. 1986;204:150–153
  205. Timothy AR, Tucker AK, Park WM, Cannell MA. Osteonecrosis in Hodgkin’s disease. Br J Radiol. 1978;51:328–332
  206. Felix C, Blatt J, Goodman MA, Medina J. Avascular necrosis of bone following combination chemotherapy for acute lymphocytic leukemia. Med Pediatr Oncol. 1985;13:269–272
  207. Jones JP. Etiology and pathogenesis of osteonecrosis. Semin Arthroplast. 1989;2:160–168
  208. Roebuck DJ. Skeletal complications in pediatric oncology patients. RadioGraphics. 1999;19:873–885
  209. Fletcher BD. Effects of pediatric cancer therapy on the musculoskeletal system. Pediatr Radiol. 1997;27:623–636
  210. Ecklund K, Laor T, Goorin AM, Connolly LP, Jaramillo D. Methotrexate osteopathy in patients with osteosarcoma. Radiology. 1997;202:543–547
  211. Schwartz AM, Leonidas JC. Methotrexate osteopathy. Skeletal Radiol. 1984;11:13–16
  212. Gnudi S, Butturini L, Ripamonti C, Avella M, Bacci G. The effects of methotrexate (MTX) on bone. A densitometric study conducted on 59 patients with MTX administered at different doses. Ital J Orthop Traumatol. 1988;14:227–231
  213. O’Regan S, Melhorn DK, Newman AJ. Methotrexate-induced bone pain in childhood leukemia. Am J Dis Child. 1973;126:489–490
  214. Neglia JP. Childhood cancer survivors. Past, present, and future [editorial]. Cancer. 1994;73:2883–2885
  215. Meadows AT, D’Angio GJ, Evans AE, Harris CC, Miller RW, Mike V. Oncogenesis and other late effects of cancer treatment in children. Radiology. 1975;114:175–180
  216. Smith MB, Xue H, Strong L. Forty-year experience with second malignancies after treatment of childhood cancer: analysis of outcome following the development of the second malignancy. J Pediatr Surg. 1993;28:1342–1348
  217. Tucker MA, D’Angio GJ, Boice-JD J. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 1987;317:588–593
  218. Hawkins MM, Wilson ML, Burton HS. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Nat Cancer Inst. 1996;88:270–277
  219. Hayes AJ, Li LY, Lippman ME. Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment. BMJ. 1999;318:853–856
  220. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs. 1999;58:17–38

PII: S0305-7372(00)90180-4

doi: 10.1053/ctrv.2000.0180

Cancer Treatment Reviews
Volume 26, Issue 5 , Pages 363-376 , October 2000

Article Tools